Allergan, Gedeon Richter receive FDA approval for schizophrenia treatment

DUBLIN and BUDAPEST — Allergan and partner Gedeon Richter announced Thursday that the Food and Drug Administration had approved their Vraylar (caripazine) capsules. The new drug is intended to treat schizophrenia and bipolar I disorder in adults.

“We are pleased with the FDA approval of VRAYLAR, which represents an important new treatment option for adults living with bipolar I disorder and schizophrenia to help address the unmet medical needs of people with these complex conditions,” David Nicholson, EVP and president of Global R&D brands at Allergan, said. “This approval reinforces our deep commitment to the mental health community, as we continue to build our robust CNS portfolio.”